Pablo G. Legorreta - 05 Nov 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: CEO, Chairman of the Board, Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Issuer symbol: RPRX
Transactions as of: 05 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Nov 2025, 16:19:27 UTC
Previous filing: 08 Aug 2025
Next filing: 13 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Legorreta Pablo G.	CEO, Chairman of the Board, Director	C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta	07 Nov 2025	0001507678

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+36,559	+4%	$0.000000	940,955	05 Nov 2025	Direct	F1
holding	RPRX	Class A Ordinary Shares						1,040,410	05 Nov 2025	By Legorreta Children 2002 Trust
holding	RPRX	Class A Ordinary Shares						901,590	05 Nov 2025	By GST-Exempt Legorreta 2012 Family Trust
holding	RPRX	Class A Ordinary Shares						600,000	05 Nov 2025	By Legorreta 2023 SR Trust
holding	RPRX	Class A Ordinary Shares						460,139	05 Nov 2025	By Legorreta Investments LLC
holding	RPRX	Class A Ordinary Shares						292,190	05 Nov 2025	By Tata MC 35 Ltd.
holding	RPRX	Class A Ordinary Shares						123,310	05 Nov 2025	By IRRA
holding	RPRX	Class A Ordinary Shares						118,500	05 Nov 2025	By SEP/IRA
holding	RPRX	Class A Ordinary Shares						41,306	05 Nov 2025	By GST-Exempt Legorreta 2020 Family Trust
holding	RPRX	Class A Ordinary Shares						10,000	05 Nov 2025	By Son
holding	RPRX	Class A Ordinary Shares						10,000	05 Nov 2025	By Daughter
holding	RPRX	Class A Ordinary Shares						6,930	05 Nov 2025	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.